Adverse Reactions, Immunity and Vaccines

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

SEPTEMBER 10, 2020

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies. subtilis spores engineered to present SARS-CoV-2 antigens to the mucosal immune system.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

Herd immunity is nice – but what about me?

pharmaphorum

JULY 5, 2021

Shahrokh Shabahang discusses why we need a personalised approach to COVID-19 immunity testing. While these numbers do tell us something about the relative immunity of the population writ large, they don’t tell us anything about our own, personal immune profiles. However, we’ve also found a number of outliers.

Immunity

Immunity Immunization Health and Personal Care Stores Vaccines

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

pharmaphorum

DECEMBER 9, 2020

Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. of participants. of participants.

Vaccines

Vaccines Adverse Reactions Documentation Immunity

Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData

Express Pharma

JUNE 12, 2024

Moderna has announced positive Phase III data for its COVID-19/influenza combination vaccine, mRNA-1083. Stephanie Kurdach, Infectious Disease Analyst at GlobalData, comments, “Moderna’s mRNA-1083 combines the mRNA-1010 seasonal influenza vaccine candidate with the mRNA-1283 next-generation Covid-19 vaccine candidate.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

How advanced technology can streamline the COVID-19 vaccine rollout

pharmaphorum

MARCH 2, 2021

Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.

Vaccines

Vaccines Adverse Reactions Documentation Labelling

Mix and match regimen of AZ and Pfizer COVID jabs works well

pharmaphorum

JUNE 29, 2021

Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. Third AZ dose generates strong variant response.

Vaccines

Vaccines Adverse Reactions Immunization Immunity

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines

Vaccines Adverse Reactions Immunity Immunization

Health Canada grants expanded authorisation for Novavax’s Covid-19 vaccine

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

FDA approves first gene therapy for high-risk early bladder cancer

European Pharmaceutical Review

DECEMBER 19, 2022

Treatment and care of patients with high-risk NMIBC, including those with CIS often involves removing the tumour and the use of the BCG vaccine to reduce the risk that the cancer will recur. The FDA stated that individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.

Adverse Reactions

Adverse Reactions Immunity Immunization Vaccines

What Are The Signs Of A Vaccine Injury?

PharmaShots

FEBRUARY 28, 2023

The signs and symptoms of a potential vaccine injury can vary. Other adverse reactions that could be attributed to a vaccine injury include neurological disorders such as seizures, autoimmune diseases, and allergic reactions. Read on to learn more about vaccine injuries and their symptoms.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

UK poised to announce booster COVID jabs for over-50s

pharmaphorum

SEPTEMBER 14, 2021

The UK government is due to announce a large-scale booster vaccine campaign against COVID-19 for all adults aged 50 and over later today, adding to its plan for third doses for people with weakened immune systems. A third dose of the shot was approved by the MHRA last week. Resistance to US booster plans.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

Pharmaceutical Technology

MAY 15, 2023

A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.

Adverse Reactions

Adverse Reactions Mayo Clinic Immunity Immunization

First chikungunya vaccine approved

European Pharmaceutical Review

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.

Vaccines

Vaccines Adverse Reactions Immunity Immunization

BMS Submits Application for Abecma® for Relapsed or Refractory Multiple Myeloma

LifeProNow

APRIL 19, 2023

The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.

Adverse Reactions

Adverse Reactions Vaccines Immunity Immunization

Common Hashimoto’s Patterns Seen in the GI-MAP Test

The Thyroid Pharmacist

NOVEMBER 8, 2024

It is a comprehensive stool-based test that addresses a wide range of microbial targets (bacteria, opportunistic organisms, viruses, parasites, fungi, and normal flora), as well as immune and digestive markers. This can allow the body’s immune system to attack the thyroid (or elsewhere) versus the infection. [17]

Immunity

Immunity Immunization Diabetes Adverse Reactions

Pharmacist Digest

Non-vaccine nasal spray could protect against COVID-19

Herd immunity is nice – but what about me?

Trending Sources

FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel

Moderna’s Covid-19/influenza vaccine phase III data highlights potential of mRNA technology for infectious diseases: GlobalData

How advanced technology can streamline the COVID-19 vaccine rollout

Mix and match regimen of AZ and Pfizer COVID jabs works well

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Health Canada grants expanded authorisation for Novavax’s Covid-19 vaccine

FDA approves first gene therapy for high-risk early bladder cancer

What Are The Signs Of A Vaccine Injury?

UK poised to announce booster COVID jabs for over-50s

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

First chikungunya vaccine approved

Contents

BMS Submits Application for Abecma® for Relapsed or Refractory Multiple Myeloma

Common Hashimoto’s Patterns Seen in the GI-MAP Test

Stay Connected